There have been no open-market insider trades at Clearside Biomedical, Inc. in the last 12 months.
Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
There have been no open-market insider trades at Clearside Biomedical, Inc. in the last 12 months.
Zooming out by quarter: No open-market insider buying or selling in the last full quarter. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Feb 24, 2025 | Thorp Clay | Director | Buy | 15,000 | $0.92 | $14K | SEC |
| Nov 4, 2024 | Chong Ngai Hang Victor | Executive Officer | Buy | 36,500 | $1.00 | $36K | SEC |
| Jun 24, 2024 | Chong Ngai Hang Victor | Executive Officer | Buy | 23,500 | $1.06 | $25K | SEC |
| May 15, 2024 | YERXA BENJAMIN R | Director | Buy | 7,813 | $1.31 | $10K | SEC |
| Apr 19, 2024 | Gibney Anthony S | Director | Buy | 6,710 | $1.25 | $8K | SEC |
| Apr 19, 2024 | Gibney Anthony S | Director | Buy | 93,290 | $1.30 | $121K | SEC |
| Mar 20, 2024 | Chong Ngai Hang Victor | Executive Officer | Buy | 30,000 | $1.60 | $48K | SEC |
| Feb 9, 2024 | WHITMORE BRADFORD T | 10% Owner | Buy | 444,444 | $1.35 | $600K | SEC |
| Jan 19, 2024 | LASEZKAY GEORGE M | CEO | Sell | 18,000 | $1.27 | $23K | SEC |
| Jan 19, 2024 | Deignan Charles A. | CFO | Sell | 12,900 | $1.28 | $17K | SEC |
| Nov 1, 2023 | WHITMORE BRADFORD T | 10% Owner | Buy | 600 | $0.69 | $414 | SEC |
| Nov 1, 2023 | WHITMORE BRADFORD T | 10% Owner | Buy | 64,366 | $0.74 | $48K | SEC |
| Nov 1, 2023 | WHITMORE BRADFORD T | 10% Owner | Buy | 70,812 | $0.73 | $52K | SEC |
| Oct 4, 2023 | Hutson Nancy J | Director | Buy | 10,000 | $0.86 | $9K | SEC |
| Sep 25, 2023 | Thorp Clay | Director | Buy | 10,000 | $0.86 | $9K | SEC |
There were no open-market insider trades in CLSD in the last 12 months. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
No congressional trades in CLSD were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).